Beigene

This early-stage study tests a new drug called BGB-45035 for safety and how the body processes it. First, healthy volunteers receive single or multiple doses. Then, people with autoimmune skin diseases like atopic dermatitis (eczema) or prurigo nodularis receive the drug to check…

This study tests a drug called tislelizumab in people with advanced solid tumors that have a specific genetic feature (MSI-H or dMMR). The drug helps the immune system attack cancer cells. About 200 adults who have already tried other treatments will receive the drug and be monit…

This study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …

This study is testing a new drug called BGB-11417 for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The drug works by blocking a protein that helps cancer cells survive. The study will find safe doses and see if the drug …

This study tests the drug zanubrutinib in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take the drug by mouth, and doctors will m…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…

This study compares two drug combinations for people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. About 780 participants will receive either zanubrutinib plus an anti-CD20 antibody or lenalidomide plus rituximab. The goal is to…

This early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS …

This early-phase study tests a new drug called BGB-B455 in people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find the safest dose and understand side effects. About 90 participants will join, and the study has two parts: f…

This early-stage study tests a new drug called BG-T187, which is designed to attach to two cancer-related targets (EGFR and MET) to attack tumor cells. About 87 adults with advanced solid tumors that have not responded to prior treatments will receive the drug alone or with other…

This study is observing people with Waldenström macroglobulinemia (a rare blood cancer) who are taking the drug zanubrutinib. Researchers want to see how well the drug works and how safe it is, especially in people with certain genetic mutations and from racial and ethnic minorit…